Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00099684 · ClinicalTrials.gov registry record · NA

Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults

A NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
44
Enrollment target
20
Study locations

NCT00099684 is a NA study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 44 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00099684, a NA study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
44 participants
Enrollment target
20
Study locations

Study Summary

Anti-HIV drugs, especially protease inhibitors (PIs), have been linked to lipid metabolism problems, including elevations in low density lipoprotein cholesterol (LDL-c), triglycerides, and total cholesterol. Ezetimibe is a lipid-controlling drug; statins are part of another class of lipid-lowering drugs popularly prescribed to people with high cholesterol. The purpose of this study is to determine the safety, effectiveness, and tolerability of ezetimibe in combination with statin therapy in adults who are taking anti-HIV drugs and have high cholesterol. Study hypothesis: In HIV infected adults, ezetimibe in combination with statin therapy will result in significantly lower LDL-c compared to statin therapy alone.

Conditions Studied

HIV Infections

Interventions

  • DRUG Ezetimibe

Study Locations (20)

California

  • UCLA School of Medicine - Los Angeles
  • University of Southern California - Los Angeles
  • University of California, San Diego Antiviral Research Center - San Diego
  • San Francisco General Hospital - San Francisco
  • San Mateo County AIDS Program - Stanford
  • Santa Clara Valley Medical Center - Stanford
  • Stanford University - Stanford
  • Willow Clinic - Stanford

Illinois

  • Rush-Presbyterian/St. Lukes (Chicago) - Chicago
  • Cook County Hospital Core Center - Chicago
  • Feinberg School of Medicine, HIV/ACTU - Chicago, 60611-3015

Indiana

  • Indiana University Hospital - Indianapolis
  • Wishard Hospital - Indianapolis

Alabama

  • University of Alabama at Birmingham - Birmingham

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Florida

  • University of Miami - Miami

Hawaii

  • University of Hawaii - Honolulu

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2005-11
Est. Completion 2007-05
Phase NA

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00099684

The ClinicalTrials.gov registry entry for NCT00099684 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (90% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Ezetimibe is the first listed.

NCT00099684 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Illinois, Indiana.

Frequently Asked Questions

What is clinical trial NCT00099684 about?

NCT00099684 is a clinical study titled "Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults". Anti-HIV drugs, especially protease inhibitors (PIs), have been linked to lipid metabolism problems, including elevations in low density lipoprotein cholesterol (LDL-c), triglycerides, and total cholesterol. Ezetimibe is a lipid-controlling drug; statins are part of another class of lipid-lowering d...

What is the current status of trial NCT00099684?

This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2005-11. Estimated completion is 2007-05.

What conditions does trial NCT00099684 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00099684?

The interventions under investigation include: Ezetimibe (DRUG).

Who is sponsoring clinical trial NCT00099684?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00099684 being conducted?

This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.